Other new anti‐obesity drugs, such as the glucose‐dependent insulinotropic polypeptide and GLP‐1 receptor agonist tirzepatide,58 have the potential to be effective for managing obesity in patients with BBS and may be valuable in combination with setmelanotide in the future. The gene discussed is GLP1R; the disease is Bardet-Biedl syndrome.